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Abstract: Osteogenesis imperfecta is a diverse group of rare genetic disorders that result in 
varying degrees of bone frailty and skeletal deformities. There are few nutrition 
recommendations for infants and children with osteogenesis imperfecta, who are at an increased 
risk of overweight and obesity, or who may experience feeding difficulties that can result in 
underweight and malnutrition.  
A ten-month-old male with severe osteogenesis imperfecta requiring enteral nutrition support 
was admitted to a community hospital for treatment of respiratory distress and a high fever. The 
patient was intubated for eight days, but his hospital stay was then prolonged because he 
continued to experience breathing difficulties, intermittent fevers, and worsening gastrointestinal 
distress.  We implemented several changes to the patient’s nutrition prescription in an attempt to 
improve his feeding tolerance, including switching the patient to a partially hydrolyzed formula, 
providing a probiotic designed to alleviate digestive distress, and recommending a laxative 
regimen. The patient’s health, however, continued to deteriorate in the hospital, and he had to be 
reintubated after two months. At this point, the patient had developed an ileus and lower 
extremity edema, and he was unable to tolerate trophic feeds. After discontinuing tube-feedings, 
the patient no longer experienced abdominal distension or agitation, and his lower extremity 
edema improved. He passed away nineteen days after discontinuing enteral nutrition support.  
This case describes the difficulties of meeting the nutritional needs of an infant with severe 
osteogenesis imperfecta and feeding intolerance. Although withholding nutrition was challenging 
ethically, this case illustrates the benefits of discontinuing nutrition support in a terminally ill 
infant. Recognizing the benefits and burden of nutrition intervention is critical for providing 
individualized care and optimizing a patient’s quality of life.  
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I. An Infant with Osteogenesis Imperfecta: His History  
A ten-month-old male was admitted to the pediatric intensive care unit (PICU) of a 
community hospital for treatment of respiratory distress and a fever of 41.5°C. His gestation had 
been complicated by moderately severe skeletal deformities, including shortened long bones and 
an undermineralized skull, which were noted on an ultrasound examination during the third 
trimester. He was born at thirty-nine weeks gestation via C-section. At birth, he had short and 
bowed arms and legs with limited movement, thin ribs that had fractured during gestation, and a 
relatively large head, all of which were consistent with a diagnosis of osteogenesis imperfecta 
(OI).1 He also had difficulty breathing and required continuous positive airway pressure (CPAP) 
therapy. Genetic testing performed at the University of Washington Collagen Diagnostic 
Laboratory confirmed the diagnosis of type II/type III OI (COL1A1 Gly676Asp mutation).  
A series of infections starting at two months of age, including pneumonia and presumed 
sepsis treated with antibiotics for seven days, extended his stay in the neonatal intensive care unit 
(NICU). During his NICU stay, he completed three courses of pamidronate, a drug used to treat 
OI by reducing the risk of bone fracture and preventing long bone deformities.2 However, he 
continued to experience breathing difficulties, with marked congestion and respiratory distress 
occurring during feedings. Additionally, he exhibited retching and back arching during feedings, 
which is typical of infants suffering from gastroesophageal reflux disease (GERD).3 At three 
months of age, a gastrostomy feeding tube was surgically placed so he could eat without 
experiencing distress. 
He was discharged from the NICU when he was four months old and, given the severity of 
his illness, was followed by a palliative care team. After discharge, the patient continued to 
require oxygen therapy, diuretics to prevent fluid overload, calcium and sodium chloride 
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supplements to counteract mineral losses resulting from diuretic use, and acetaminophen and 
narcotics for chronic pain management.  He also started attending an outpatient pediatric 
gastroenterology clinic so that his growth and tube-feeding regimen could be evaluated. 
However, the infant was hospitalized on multiple occasions for treatment of acute respiratory 
distress and pneumonia throughout the six months following his discharge from the NICU. The 
patient experienced severe weight loss (0.5 kg, or 15% usual body weight) during the his most 
recent hospitalization at another institution, from which he had been discharged less than two 
weeks before the current hospitalization, possibly because he was fluid-restricted and could not 
receive his usual diet. Three days before the current hospitalization, the pediatric 
gastroenterology team noted a weight of 3.54 kg and recommended increasing his caloric intake 
to compensate for his recent weight loss. His new nutrition prescription was Enfamil Enfacare 
mixed to 27 kcal/oz., given at a rate of 19 mL/hr. continuous for 24 hrs. to provide 116 kcal/kg 
and 3.2 gm protein/kg.  
II. Hospital Course 
The patient started receiving high-flow nasal cannula oxygen therapy immediately after 
being admitted to the PICU. He was intubated on the second day of hospitalization, as his 
respiratory status had continued to decline. He was successfully extubated on day ten, but he 
required high-flow nasal cannula oxygen therapy through day fifteen of hospitalization. After 
extubation, he also experienced signs and symptoms of benzodiazepine and narcotic dependence 
(a fever of 38.7ºC, heart rate 139-197 beats per minute). On day seventeen, he started receiving 
what would have been a three-day course of pamidronate, but the drug caused him to develop an 
acute kidney injury after two days (creatinine elevated for 9 days, 0.46-0.70 mg/dL). The patient 
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also began to experience intermittent fevers on day twenty-one of hospitalization, despite having 
recently completed a fourteen-day antibiotic course. 
The patient’s hospital stay was prolonged by several weeks because he continued to 
experience intermittent low-grade fevers, episodes of tachycardia (heart rate up to 217 beats per 
minute), gastrointestinal distress, continued difficulty with benzodiazepine and narcotic 
dependence, electrolyte disturbances, and a new occult lower extremity fracture that likely 
occurred while the patient was being cleaned. By day forty-five of hospitalization, the patient’s 
overall health had improved significantly and the medical team started planning for discharge. 
However, on day fifty-five the patient began to experience tachycardia and agitation again, 
which caused him to have an increased need for oxygen. Three days later, he started to develop 
mild but persistent lower extremity edema. The patient’s respiratory condition deteriorated 
rapidly on day sixty and he had to be reintubated. His mother requested a do-not-resuscitate 
order before the patient was extubated on day sixty-seven, as it had become apparent that he 
would continue to suffer from life-long respiratory distress, in addition to now having developed 
an ileus and lower extremity edema. At this point, the palliative care team recommended 
discontinuing any intervention that caused pain or discomfort. 
III. Nutrition Assessment and Intervention 
On admission to the PICU, the patient weighed 3 kg (Z score: -9.68), but this weight was 
probably inaccurate because the patient was dehydrated (serum osmolality 309 mOsm/kg). 
However, we used this weight to avoid overfeeding the patient until we were able to obtain an 
accurate weight. His length on admission was 61 cm (Z score: -5.47). This measurement was 
probably inaccurate as well because the patient’s severe skeletal deformities and high risk of 
bone fracture prevented the nurses from stretching his limbs for accurate measurement. His 
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weight-for-length was below the first percentile. We estimated his ideal body weight (IBW) to be 
5.5 kg, based on weight-for-length at the fifth percentile. According to the recommendations of a 
geneticist and OI expert consulted by the hospital, a safe weight gain goal for this patient was 8-
10 gm/day.  
Since we could not use indirect calorimetry to measure actual energy expenditure, we 
estimated the patient’s energy needs using the Dietary Reference Intakes/Institute of Medicine 
(DRI/IOM) equation with a stress factor of 1.5 for several reasons.4 First, the patient’s weight-
for-length percentile was significantly below the range considered adequate for individuals with 
OI. Second, the patient had a history of prolonged hospitalizations and significant weight loss in 
the months preceding this hospitalization. Third, the patient’s high fever on admission increased 
his basal metabolic rate and energy expenditure.  However, we used the patient’s actual body 
weight (ABW) instead of his IBW because overfeeding can extend the duration of mechanical 
ventilation and increase the risk of infection.5 We estimated the patient’s energy needs to be                     
95 kcal/kg, and we estimated his protein needs to be 2-3 gm/kg of ABW using the 
recommendations from the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) 
for nutrition support of a critically ill child.4  
We initially diagnosed the patient as being underweight related to his prolonged and frequent 
hospitalizations for respiratory distress, as evidenced by his weight-for-length below the first 
percentile. Our initial nutrition recommendation was to continue tube-feedings using Enfamil 
Enfacare mixed to 27 kcal/oz. at a rate of 13 mL/hr. continuous over 24 hrs. to provide 94 
kcal/kg and 2.6 gm protein/kg. Additionally, we requested approval from the medical team to 
obtain daily weights so that we could adjust the nutrition prescription as necessary. Given the 
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patient’s history of respiratory distress, we monitored serum lactate levels to ensure safe enteral 
feedings. We also monitored signs of discomfort associated with GERD.  
IV. Nutrition Follow-Up 
We monitored the patient daily during multidisciplinary team rounds and updated his 
nutrition care plan twice weekly. After he was extubated, we estimated his energy needs to be 
110-120 kcal/kg using the DRI/IOM equation for his IBW. We adjusted his tube-feeding rate to 
19 mL/hr. continuous over 24 hrs. to provide 116 kcal/kg and 3.2 gm protein/kg. Once the 
nursing staff was able to obtain a true weight on day twelve of hospitalization, we updated his 
nutrition prescription to a new goal rate of 20 mL/hr. continuous over 24 hrs. to provide                          
115 kcal/kg and 3.2 gm/kg. During the next two weeks, the patient tolerated his tube feedings 
well, though we documented episodes of discomfort, retching, and abdominal distention. For this 
reason, on day sixteen the patient’s mother requested that his tube-feeding goal rate be reduced 
to 19 mL/hr.  
The patient continued to retch and experience abdominal discomfort associated with feeds, 
despite frequent venting of his feeding tube and good bowel movements. We implemented 
several nutrition changes in an attempt to improve the patient’s feeding tolerance. On day forty-
one, the patient started to receive one daily capsule of Culturelle, a probiotic designed to 
alleviate digestive distress.6 On day forty-four, we changed his nutrition prescription to Pediasure 
Peptide 1.0 at a goal rate of 17 mL/hr. continuous over 24 hrs. to provide 112 kcal/kg and 3.4 gm 
protein/kg. The reasons for this formula change were twofold: first, we hoped that a partially 
hydrolyzed formula would improve gastric transit time, decreasing the risk of reflux; secondly, 
because the patient would soon be a year old, a toddler formula would meet his nutritional needs 
better.7, 8 In preparation for possible discharge, we adjusted his tube-feedings to run over a 21-hr. 
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cycle starting on day forty-seven. However, on day fifty-two the patient’s mother reported that 
he had continued to experience distress associated with feedings, and she asked that his tube-
feedings return to a 24-hr. cycle. Because of continued reports of retching and abdominal 
distension, and the thought that it might be contributing to the child’s increased discomfort, we 
discontinued Culturelle on day fifty-seven. As the patient’s mother was also concerned that a 
slow transit time was responsible for abdominal distension and pain, we gave the patient a 
laxative every other day from days sixty through seventy.  
When the patient was reintubated on day seventy, we adjusted his tube-feedings to prevent 
overfeeding. This time, we estimated his energy needs to be 70 kcal/kg using the DRI/IOM 
equation for his ABW without stress factors because he was experiencing worsening feeding 
intolerance. His new tube-feeding prescription was Pediasure Peptide 1.0 at a goal rate of 12 
mL/hr. continuous over 24 hrs. to provide 73 kcal/kg and 2.2 gm protein/kg. Nonetheless, the 
nursing staff was unable to advance the patient’s feeds to the prescribed goal rate because of his 
continued abdominal distension and increasing need for pain management. Radiographic 
imaging obtained on day sixty-six confirmed the presence of an ileus, and the pediatric surgery 
team placed a temporary rectal tube to relieve the patient’s colonic gaseous distension. 
Subsequently, we adjusted the tube-feeding regimen to a goal rate of 5 mL/hr. to provide the 
benefits of trophic feeding without exacerbating his gastrointestinal discomfort.9  
After multiple failed attempts to provide trophic feeds, the palliative care team recommended 
withholding nutrition because the tube-feedings were a source of pain. According to his mother’s 
wishes, the patient received only occasional comfort feeds starting on day seventy. However, on 
day eighty-one of hospitalization, the patient’s extended family convinced his mother to restart 
tube-feedings at a rate of 1 mL/hr. He experienced adverse reactions to the tube-feedings, 
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including increased agitation and loose stools. After this episode, the palliative care team met 
with the entire family to explain the goals of comfort-care measures. The meeting helped 
reassure the family that the infant was not “starving”, and they no longer requested that tube-
feedings be restarted. The medical team slowly decreased maintenance intravenous (IV) fluids 
and diuretic use to avoid causing a rapid shift in fluid and/or electrolyte balance. The patient also 
continued to receive frequent doses of narcotics and benzodiazepines for pain management and 
to prevent agitation. As the patient became more comfortable, he also became more attentive to 
and engaged with his environment, though he did not talk or play. On day eighty-nine, the 
patient passed away peacefully surrounded by his family. 
V. Discussion 
OI is a group of rare genetic disorders characterized by bone fragility and deformity. 
Spontaneous mutations in the genes that encode collagen, the most abundant protein in the 
human body, are responsible for the majority of cases.10 OI has an incidence of 0.5-1/10,000 
births, and a prevalence of approximately 25,000-50,000 individuals in the United States.1, 11, 12 
In addition to skeletal frailty, OI may cause thoracic kyphoscoliosis, decreased pulmonary 
function, valvular heart disease, hearing loss, tooth discoloration, and blue or gray sclerae.10, 12 
Abnormal connective tissue metabolism may result in heat intolerance, elevated body 
temperature, tachypnea and tachycardia.12  
Most autosomal dominant forms of OI are caused by mutations in COL1A1 and COL1A2, 
which encode type 1 collagen—an integral component of bone extracellular matrix that provides 
a framework for the deposition of hydroxyapatite crystals.1 Type 1 collagen is a heterotrimer 
consisting of two α1(I) and one α2(I) chains, and featuring a helical domain with a repeating 
motif of amino acids: Gly-X-Y.10 The stability and tensile strength of mature type 1 collagen 
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fibrils are a result of numerous post-translational modifications, including the hydroxylation of 
prolyl and lysyl residues, as well as interchain covalent bond formation.10, 13  
The exact mechanisms by which defective collagen synthesis results in brittle bones is not 
known, but the leading hypothesis is that defective synthesis or defective collagen deposition 
delays the bone mineralization process. Paradoxically, most individuals with OI have increased 
mineral bone content, albeit decreased collagenous matrices and altered hydroxyapatite crystal 
properties. These defects can impair signal transduction pathways responsible for the 
differentiation and/or accumulation of osteoblasts. It is likely that these mechanisms are 
responsible for the low trabecular bone volume, increased number of osteoblasts, and increased 
bone turnover rate observed in individuals with OI. Furthermore, defects in type 1 collagen 
synthesis can result in lung parenchymal abnormalities that restrict pulmonary function, which 
was the case of this patient. Poor ventilation results in ineffective clearance of lung secretions, 
which increases the risk of respiratory infections.1 In some cases, rib cage abnormalities and 
changes in chest wall volume also contribute to altered breathing patterns.14 Not surprisingly, the 
primary cause of morbidity and mortality among individuals with OI is pulmonary dysfunction, 
including infections and progressive-restrictive pulmonary diseases.10, 14  
The 1979 Sillence classification provides a framework for categorizing OI based on clinical 
severity: type I (mild), type II (lethal), type III (severe), and type IV (moderate).10 However, the 
advent of genetic testing has made it possible to distinguish up to fifteen types of OI to date, 
some of which are inherited recessively. Recent discoveries of new mutations and the evolving 
understanding of the heterogeneity of OI makes it difficult to establish genotype/phenotype 
relationships. As such, the current classification of OI is clinically ambiguous, though it 
continues to provide a framework for understanding disease progression and expectations.1 
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Nonetheless, it is well established that most deleterious mutations resulting in severe or lethal OI 
are Gly substitutions in the helical domain.1, 13 In particular, substitutions resulting in branched 
chain or electrically charged amino acids are most disruptive to the structural conformation of 
the helical domain, as they introduce undesirable electrostatic interactions and steric 
hindrance.10,13 Furthermore, the severity of OI depends on the location of the mutation. Type 1 
collagen folds from the C-terminus towards the N-terminus; thus, Gly mutations closer to the C-
terminus have the potential to disrupt a larger portion of the helix and result in more severe 
forms of OI. Bodian and colleagues predict Gly Asp, Arg, Val, and Glu mutations after 
position 334 would result in lethal OI.15 Our patient with a COL1A1 Gly676Asp mutation was 
within this parameter. 
A paucity of evidence regarding nutritional recommendations for individuals with OI makes 
it difficult to assess growth and to estimate macronutrient and micronutrient needs. Individuals 
affected by OI tend to experience varying degrees of skeletal deformities, short stature, and 
limited mobility. For this reason, the World Health Organization (WHO) and Centers for Disease 
Control and Prevention (CDC) growth charts will overestimate the weight, length/height, weight-
for-length, and BMI of infants and children with OI. For this population, a surrogate marker of 
adequate growth is weight-for-length or BMI-for-age between the 10th and 85th percentile. The 
estimated energy requirements (EER) are also likely to overestimate the true energy needs of 
infants and children with OI. If growth is not followed closely, some individuals may easily 
become overweight or obese. Overweight or obesity will increase stress on bones and joints, 
exacerbate mobility problems, increase the risk of pressure ulcers in individuals with severely 
restricted mobility, and decrease the overall quality of life. Whenever energy intake has to be 
reduced, healthcare professionals should ensure that individuals with OI have adequate intake of 
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protein and micronutrients by using the recommended dietary allowance (RDA) values as a 
guideline.1   
Nutrition cannot solve defects in collagen synthesis, but ensuring adequate micronutrient 
intake should maximize the body’s capacity for bone mineralization and overall bone health, 
particularly in patients with less severe varieties of OI. Individuals with OI should consume a 
balanced diet that meets the RDA value of all micronutrients—especially that of calcium, 
phosphorus, magnesium, and vitamins A, D, and C, all of which are required for optimal bone 
health. At this time, there is no scientific consensus on vitamin D intake for individuals with OI. 
No research has been done to investigate the benefit of vitamins A and K supplements for 
individuals with OI. Nonetheless, intake of high doses of vitamin C exceeding the RDA value 
have not proven effective in improving collagen synthesis or treating symptoms of OI; therefore, 
Shapiro and colleagues encourage vitamin C intake that meets the RDA value to promote bone 
health and healing after fractures.1  
Infants and children with severe forms of OI may suffer from GERD as a result of skeletal 
abnormalities and hypotonia. Weak facial joints may impede effective latching to the breast or 
the bottle, or result in difficulty establishing a safe and effective suck-and-swallow pattern during 
feedings. Strategies to maximize oral feeding include specialty bottle nipples that ease the effort 
of latching and swallowing, upright positioning during and after feedings to minimize reflux, and 
small frequent feedings to decrease the risk of spitting and vomiting. Lactation consultants and 
speech therapists may provide targeted therapy to improve oral intake. However, if these 
strategies fail, a Nissen fundoplication may be necessary to relieve GERD symptoms. Infants 
who continue to have trouble latching or swallowing may also require a feeding tube to receive 
adequate nutritional intake.1  
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In this case, the patient’s severe feeding intolerance limited our ability to provide tube-
feedings adequate in calories, vitamins, and minerals (Tables 1 and 2).  It is worth noting that the 
patient’s intake of vitamin D, phosphorus and magnesium was below the established RDA or 
adequate intake (AI) value for most of his hospitalization. These nutrients are required for bone 
health and development, but we were unable to provide a neonatal multivitamin such as Poly-Vi-
Sol because pamidronate can increase serum levels of 1,25-dihydroxyvitamin D.2  Consequently, 
at the beginning of this hospitalization we encouraged the patient’s mother to consult the 
outpatient endocrinologist regarding vitamin D supplements. The patient did receive phosphorus 
replacements throughout his hospital stay.  Despite inadequate magnesium intake, his serum 
magnesium levels remained within normal limits. Limited tube-feedings caused the patient’s 
average rate of weight gain to be 6.9 gm/day, which is below the recommended 8-10 gm/day 
(Table 3). This demonstrates how feeding difficulties associated with OI can result in poor 
weight gain and development.  
This case also describes a situation in which nutrition intervention resulted in decreased 
quality of life, as evidenced by abdominal distension that required relief by rectal tube 
placement, loose stools, lower extremity edema, and acute pain resulting in tachycardia. Despite 
these signs of feeding intolerance, withholding nutrition proved challenging because the severity 
of OI was deemed “potentially lethal” but not unequivocally terminal. As a result, some staff and 
extended family members thought that the infant was “being starved,” and they did not 
understand the reasons for withholding tube-feedings. This situation put unnecessary stress on 
the patient’s mother, who did understand the benefits of withholding nutrition but was convinced 
by her family to restart tube-feedings. Restarting tube-feedings, however briefly, caused pain and 
decreased the patient quality of life.  
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Table 1: Calorie and protein content of tube-feedings provided to an infant with severe osteogenesis imperfecta. 
Day of Hospitalization Days 2-10 Days 12-16 Days 16-44 Days 44-60 Days 60-66 Days 66-70 
 
Nutrition Prescription 
Enfamil Enfacare 
27 kcal/oz. 
Rate: 13 mL/hr. 
Enfamil Enfacare 
27 kcal/oz. 
Rate: 20 mL/hr. 
Enfamil Enfacare 
27 kcal/oz. 
Rate: 19 mL/hr. 
Pediasure 
Peptide 1.0 
Rate:  17 mL/hr. 
Pediasure 
Peptide 1.0 
Rate: 12 mL/hr. 
Pediasure 
Peptide 1.0 
Rate: 5 mL/hr. 
Calories (kcal/kg) 94* 115 116 112 73* 30* 
Protein (gm/kg) 2.6 3.2 3.2 3.4 2.2 0.91 
 
*Denotes instances in which the nutrition prescription provided calories below the levels we estimated the patient would need for full 
growth and development (110-120 kcal/kg). 
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Table 2: Vitamin and mineral content of tube-feedings provided to an infant with severe osteogenesis imperfecta.  
*Denotes values not meeting the RDA for age.16 
** Denotes values not meeting the adequate intake (AI) for age.1
Day of Hospitalization Days 2-10 Days 12-16 Days 16-44 Days 44-60 Days 60-66 Days 66-70 
 
Nutrition Prescription 
Enfamil Enfacare 
27 kcal/oz. 
Rate: 13 mL/hr. 
Enfamil Enfacare 
27 kcal/oz. 
Rate: 20 mL/hr. 
Enfamil Enfacare 
27 kcal/oz. 
Rate: 19 mL/hr. 
Pediasure 
Peptide 1.0 
Rate:  17 mL/hr. 
Pediasure 
Peptide 1.0 
Rate: 12 mL/hr. 
Pediasure 
Peptide 1.0 
Rate: 5 mL/hr. 
Vitamin A (IU) 1264** 1944 1847 1019 720* 300* 
Vitamin D (IU) 211** 324** 308** 408* 288* 120* 
Vitamin E (IU) 11 17 16 9.3 6.6 2.7* 
Vitamin K (mcg) 25 39 37 22** 16** 6.6** 
Thiamin (mcg) 505 778 739 1033 729 304* 
Riboflavin (mcg) 562 864 821 861 607 253* 
Niacin (mcg) 2808** 4320 4104 4132* 2916* 1215* 
Pantothenic acid (mcg) 2387 3672 3488 4132 2916 1215* 
Vitamin B6 (mcg) 188** 289** 275** 1033 729 304* 
Biotin (mcg) 17 26 25 77 55 23 
Folic acid, mcg) 73** 112 107 122* 86* 36* 
Vitamin B12 (mcg) 0.84 1.3 1.2 2.4 1.7 0.7* 
Vitamin C (mg) 45** 69 66 41 29 12* 
Calcium (mg) 334 518 492 430* 304* 127* 
Phosphorus (mg) 185** 285 271** 344* 243* 101* 
Magnesium (mg) 22** 35** 33** 81 57* 24* 
Iron (mg) 5.0* 7.8* 7.4* 5.7* 4.0* 1.7* 
Zinc (mg) 2.8* 4.3 4.1 4.8 3.4 1.4* 
Manganese (mcg) 42** 65** 62** 688** 486** 203** 
Copper (mcg) 253 389 369 344 243* 101* 
Iodine (mcg) 60** 91** 86** 40* 23* 12* 
Selenium (mcg) 7.9** 12** 11** 13* 9.2* 3.8 
Sodium (mcg) 104** 160** 152** 293** 207** 86** 
Potassium (mcg) 295** 453** 431** 396** 389** 162** 
Chloride (mg) 219** 337** 320** 413** 292** 122** 
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Table 3: Weight and weight gain rate of an infant with severe osteogenesis imperfecta.  
Day of Hospitalization 
 
Weight (kg) 
 
Cumulative Weight Gain Rate (gm/day) 
Day 0        3.54* -- 
Day 12 3.79** 20.8 
Day 19 3.65** 5.8 
Day 26 3.61** 2.7 
Day 30        3.63 3.0 
Day 45        3.73 4.2 
Day 59        3.95 6.9 
*For calculating weight gain rate, we used the weight obtained by the pediatric gastroenterology 
clinic three days before the patient was hospitalized.  
**Measurements taken when the patient’s diuretic prescription was changed and he was likely 
experiencing fluid overload.  
 
Although withholding nutrition from children is a contentious issue, A.S.P.E.N. and the 
American Academy of Pediatrics (AAP) argue that it “may be ethically acceptable when 
competent parents and the medical team concur that the intervention no longer confers a benefit 
to the child or creates a burden that cannot be justified”.17, 18 Likewise, Shapiro et al. maintain 
that in severe OI cases, palliative care is an ethical option.1 The benefits of withholding nutrition 
at the end-of-life include diminished oral secretions, which decrease the risk of aspiration and 
congestion.18 Caloric deficit also triggers ketosis and endorphin production that may increase 
feelings of well-being during terminal illness.18 Moreover, physiological adaptations at the end-
of-life prevent individuals from sensing hunger.18, 19  
On the other hand, providing nutrition to dying patients may be associated with fluid 
retention, pulmonary edema, ascites, increased bladder distension, nausea, vomiting, and 
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diarrhea.19 Providing artificial nutrition may also require additional interventions, such as 
continued electrolyte monitoring.18 However, a qualitative retrospective study of parental 
perceptions concluded that all parents interviewed were satisfied with their decision to withhold 
nutrition from their terminally ill children.20 Withholding nutrition during our patient’s final 
nineteen days improved his quality of life, as evidenced by a decrease in leg swelling, abdominal 
distension, retching, and tachycardia. The improvement in the patient’s symptoms allowed his 
family to spend more time holding him and interacting with him.  
VI. Conclusion 
Nutrition intervention in OI remains a challenge, particularly in severe cases requiring 
multiple adjustments of the nutrition prescription. This case illustrates the difficulties in 
providing enteral nutrition support to an individual with a condition for which predictive 
equations are likely to overestimate needs and for which no growth chart exists. Given the lack 
of research on nutrition therapy for OI, it is important to monitor closely the growth of infants 
and children with OI to prevent either malnutrition or overweight and obesity. As this case 
illustrates, weight-for-length and previous growth trends could be used to establish growth 
parameters and estimate energy needs for an infant with severe OI.  
Nutrition intervention can improve the nutritional status and prolong the life of infants and 
children with severe OI. However, it is important to recognize that for some patients, the burden 
of nutrition intervention can surpass the benefits it provides. In this case, we had to recognize 
that our patient’s health had declined so severely that providing tube-feedings decreased his 
quality of life. Clear and early communication with all staff and family members could have 
avoided some of the challenges of withholding artificial nutrition. Despite these difficulties, 
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withholding nutrition improved the patient’s comfort and quality of life, allowing his family to 
spend more time interacting with the patient before he passed away. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
References 
1. Shapiro, JR, Byers PH, Glorieux FH, Sponseller, PD. Osteogenesis Imperfecta: A 
Translational Approach to Brittle Bone Disease. Amsterdam: Elsevier Academic Press; 
2014.  
 
2. Beary JF, Chines AA. Osteogenesis imperfecta: Management and prognosis. UpToDate 
website. http://www-uptodate-com.libproxy.lib.unc.edu/contents/osteogenesis-imperfecta-
management-and-
prognosis?source=search_result&search=pamidronate&selectedTitle=7~76. Updated January 
2016. Accessed November 30, 2016.  
 
3. Winter, HS. Gastroesophageal reflux in infants. UpToDate website. http://www-uptodate-
com.libproxy.lib.unc.edu/contents/gastroesophageal-reflux-in-
infants?source=search_result&search=gerd%20infants&selectedTitle=1~150. Updated July 
2016. Accessed November 30, 2016.  
 
4. Corkins MR, Balint J, American Society for Parenteral and Enteral Nutrition. The A.S.P.E.N. 
Pediatric Nutrition Support Core Curriculum. 2nd ed. Silver Spring, MD: American Society 
for Parenteral and Enteral Nutrition; 2015.  
 
5. Mehta NM, Compher C, A.S.P.E.N. Board of Directors.  A.S.P.E.N. clinical guidelines: 
Nutrition support of the critically ill child. J Parenter Enteral Nutr. 2009;33(3):260-276. 
doi:10.1177/0148607109333114   
 
6. Lactobacillus: Drug Information. UpToDate website. http://www-uptodate-
com.libproxy.lib.unc.edu/contents/lactobacillus-drug-
information?source=preview&search=culturelle%20children&anchor=F186462#F186462. 
Accessed November 30, 2016.  
 
7. Frati F, Garzi A, Messina M, Carfagna L, Zagordo L, Belcastro M, Parmiani S, Sensi L, 
Marcucci F. An extensively hydrolysed cow’s milk formula improves clinical symptoms of 
gastroesophageal reflux and reduces the gastric emptying time in infants. Allergol 
Immunopathol (Madr). 2002;30(1):36-41. http://www.elsevier.es/en-revista-allergologia-et-
immunopathologia-105-articulo-an-extensively-hydrolysed-cow-s-milk-
13027473?redirectNew=true. Accessed November 7, 2016. 
 
8. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the 
European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Pediatric 
gastroesophageal reflux clinical practice guidelines: Joint recommendations of the North 
American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) 
and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition 
(ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49:498-547. 
 
 
19 
 
9. Schanler, RJ. Approach to enteral nutrition in the premature infant. UpToDate website. 
http://www-uptodate-com.libproxy.lib.unc.edu/contents/approach-to-enteral-nutrition-in-the-
premature-infant?source=search_result&search=trophic%20feeds&selectedTitle=1~12. 
Updated November 2016. Accessed November 30, 2016. 
 
10. Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016;387(10028):1657-1671. 
doi:10.1016/S0140-6736(15)00728-X  
 
11. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Osteogenesis 
imperfecta overview. NIH Osteoporosis and Related Bone Diseases National Resource 
Center website. 
http://www.niams.nih.gov/health_info/bone/osteogenesis_imperfecta/overview.asp Updated 
June 2015. Accessed November 20, 2016.  
 
12. Sinikumpu J, Ojaniemi M, Lehenkari P, Serlo W. Severe osteogenesis imperfecta type-III 
and its challenging treatment in newborn and preschool children. A systematic review. 
Injury. 2015;46(8):1440-1446. doi:10.1016/j.injury.2015.04.021  
 
13. Shoulders MD, Raines RT. Collagen structure and stability. Annu Rev Biochem.  
2009;78(1):929-958. doi:10.1146/annurev.biochem.77.032207. 
 
14. LoMauro A, Pochintesta S, Romei M, D’Angelo MG, Pedotti A, Turconi AC, Aliverti A. Rib 
cage deformities alter respiratory muscle action and chest wall function in patients with 
severe osteogenesis imperfecta. PLoS One. 2012;7(4):e35965. 
doi:10.1371/journal.pone.0035965  
 
15. Bodian DL, Madhan B, Brodsky B, Klein TE. Predicting the clinical lethality of osteogenesis 
imperfecta from collagen glycine mutations. Biochemistry. 2008;47(19):5424-5432. doi: 
10.1021/bi800026k   
 
16. Food and Nutrition Board of the Institute of Medicine, National Academy of Sciences. 
Nutrient recommendations: Dietary Reference Intakes (DRI). National Institutes of Health 
Office of Dietary Supplements website. 
https://ods.od.nih.gov/Health_Information/Dietary_Reference_Intakes.aspx. Accessed 
November 20, 2016.   
 
17. A.S.P.E.N. Ethics Position Paper Task Force, Barrocas A, Geppert C, Durfee SM, Maillet 
JO, Monturo C, Mueller C, Stratton K, Valentine, C, A.S.P.E.N. Board of Directors. 
A.S.P.E.N. Ethics Position Paper. Nutr Clin Pract. 2010;25(6):672-679. 
doi:10.1177/0884533610385429  
 
18. Diekema DS, Botkin JR, Committee on Bioethics. Clinical report—forgoing medically 
provided nutrition and hydration in children. Pediatrics. 2009;124(2):813-822. doi: 
10.1542/peds.2009-1299 
 
20 
 
19. Maillet JO, Schwartz DB, Posthauer ME. Position of the Academy of Nutrition and Dietetics: 
Ethical and legal issues in feeding and hydration. J Acad Nutr Diet. 2013;113(6):828-833. 
doi:10.1016/j.jand.2013.03.020 
   
20. Rapoport A, Shaheed J, Newman C, Rugg M, Steele R. Parental perceptions of forgoing 
artificial nutrition and hydration during end-of-life care. Pediatrics. 2013;131(5):861-869. 
doi:10.1542/peds.2012-1916 
 
 
